1Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myelome treated by high-dose therapy and haemopoietie stem cell transplantation. Myelome Subcommittee of the EBMT. European Group for Blood and Marrow Transplant[J]. Br J Haematol, 1998, 102(5): 1115-1123.
2Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group[J]. Am J Clin Oncol, 1982, 5(6): 649-655.
3de Weerdt O, van de Donk NW, Veth G, et al. Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma[J]. Neth J Med, 2001, 59(2): 50-56.
4Trieu Y, Trudel S, Pond GR, et al. Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation[J]. Mayo Clin Proc, 2005, 80 (12): 1578-1582.
5Suvannasankha A, Fausel C, Juliar BE, et al. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a hoosier oncology group trial, HEM01-21 [J]. Oncologist, 2007, 12(1): 99-106.
